• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏再同步治疗“超级应答者”患者的长期预后。

Long-term outcome of 'super-responder' patients to cardiac resynchronization therapy.

机构信息

Cardiovascular Department, University and 'Ospedali Riuniti di Trieste' Hospital, Via Valdoni, 7, 34129 Trieste, Italy.

出版信息

Europace. 2014 Mar;16(3):363-71. doi: 10.1093/europace/eut339. Epub 2013 Nov 4.

DOI:10.1093/europace/eut339
PMID:24189477
Abstract

AIMS

To evaluate the long-term changes of clinical and echocardiographic parameters, the incidence of cardiac events and parameters associated with late cardiac events in 'super-responders' to cardiac resynchronization therapy (CRT) with [CRT defibrillator (CRT-D)] or without defibrillator back-up.

METHODS AND RESULTS

In all consecutive patients treated with CRT in two Italian centres (Trieste and Udine) with left ventricular ejection fraction (LVEF) ≤0.35 at implantation (Timp) and LVEF > 0.50 1 and/or 2 years (Tnorm) after implantation, the long-term outcome and the evolution of echocardiographic parameters were assessed; factors associated with a higher risk of cardiac events, defined as hospitalization or death for heart failure (HF), sudden death, or CRT-D appropriate interventions, were also analysed. Among the 259 patients evaluated, 62 (24%) had LVEF ≥ 0.50 at Tnorm (n = 44 with at 1 year, n = 18 at 2 years). During a mean follow-up of 68 ± 30 months, one cardiac death (for HF) and eight cardiovascular events (two hospitalization for HF and six appropriate CRT-D interventions) occurred. At the last echo evaluation (Tfup) performed 51 ± 26 months after Timp, LVEF was <0.50 in five patients (>0.45 in four of them). At univariable analysis, only LV end-systolic volume evaluated at Tfup was associated with a higher risk of cardiac events during follow-up.

CONCLUSION

In 'super-responders' to CRT long-term outcome is excellent. However, cardiac events, mainly CRT-D appropriate interventions, can occur despite the persistence of LVEF > 0.50. Early identification of these patients is still an unsolved issue.

摘要

目的

评估心脏再同步治疗(CRT)“超级应答者”的临床和超声心动图参数的长期变化、心脏事件的发生率以及与晚期心脏事件相关的参数,这些患者使用的 CRT 设备带有(CRT-D)或不带有除颤器后备。

方法和结果

在意大利的两个中心(的里雅斯特和乌迪内)连续接受 CRT 治疗的所有患者中,在植入时(Timp)左心室射血分数(LVEF)≤0.35,植入后 1 年(Tnorm)和/或 2 年(Tnorm)LVEF>0.50,评估长期预后和超声心动图参数的演变;还分析了与更高心脏事件风险相关的因素,定义为心力衰竭(HF)住院或死亡、心脏性猝死或 CRT-D 适当干预。在评估的 259 例患者中,62 例(24%)在 Tnorm 时 LVEF≥0.50(n=44 例在 1 年时,n=18 例在 2 年时)。在平均 68±30 个月的随访期间,发生 1 例心脏死亡(HF 所致)和 8 例心血管事件(HF 住院治疗 2 例,CRT-D 适当干预 6 例)。在 Timp 后 51±26 个月进行的最后一次超声心动图评估(Tfup)时,5 例患者的 LVEF<0.50(其中 4 例>0.45)。在单变量分析中,仅在 Tfup 时评估的 LV 收缩末期容积与随访期间发生心脏事件的风险较高相关。

结论

在 CRT 的“超级应答者”中,长期预后良好。然而,尽管 LVEF>0.50 持续存在,仍可发生心脏事件,主要是 CRT-D 适当干预。早期识别这些患者仍然是一个悬而未决的问题。

相似文献

1
Long-term outcome of 'super-responder' patients to cardiac resynchronization therapy.心脏再同步治疗“超级应答者”患者的长期预后。
Europace. 2014 Mar;16(3):363-71. doi: 10.1093/europace/eut339. Epub 2013 Nov 4.
2
Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study.心脏再同步治疗超级反应的预测因素及其对临床结局的改善:MADIT-CRT(心脏再同步治疗的多中心自动除颤器植入试验)研究。
J Am Coll Cardiol. 2012 Jun 19;59(25):2366-73. doi: 10.1016/j.jacc.2012.01.065.
3
Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.心脏再同步治疗中左心室射血分数的正常化与室性心律失常和临床结局的风险:来自多中心自动除颤器植入试验与心脏再同步治疗(MADIT-CRT)试验的结果。
Circulation. 2014 Dec 23;130(25):2278-86. doi: 10.1161/CIRCULATIONAHA.114.011283. Epub 2014 Oct 9.
4
Cardiac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry.心脏再同步治疗除颤器与心脏再同步治疗起搏器相比,可改善 I 类心脏再同步治疗适应证患者的长期生存率:来自 Contak 意大利注册研究的数据。
Europace. 2013 Sep;15(9):1273-9. doi: 10.1093/europace/eut032. Epub 2013 Feb 24.
5
Long-Term Echocardiographic Outcome in Super-Responders to Cardiac Resynchronization Therapy and the Association With Mortality and Defibrillator Therapy.心脏再同步治疗超反应者的长期超声心动图结局及其与死亡率和除颤治疗的关联。
Am J Cardiol. 2016 Oct 15;118(8):1217-1224. doi: 10.1016/j.amjcard.2016.07.041. Epub 2016 Jul 29.
6
What We Can Learn from "Super-responders".
Card Electrophysiol Clin. 2015 Dec;7(4):781-8. doi: 10.1016/j.ccep.2015.08.019.
7
Left ventricular ejection fraction overcrossing 35% after one year of cardiac resynchronization therapy predicts long term survival and freedom from sudden cardiac death: single center observational experience.心脏再同步治疗一年后左心室射血分数超过 35%预测长期生存和免于心源性猝死:单中心观察经验。
Int J Cardiol. 2014 Mar 1;172(1):64-71. doi: 10.1016/j.ijcard.2013.12.005. Epub 2013 Dec 15.
8
Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker.心脏再同步治疗除颤器和心脏再同步治疗起搏器植入后第一年的 Lead 并发症、器械感染和临床结局。
Europace. 2013 Jan;15(1):71-6. doi: 10.1093/europace/eus247. Epub 2012 Aug 26.
9
Long-term outcome of patients with and without super-response to CRT-D.有或没有对心脏再同步化治疗除颤器(CRT-D)产生超反应的患者的长期预后
Clin Res Cardiol. 2016 Apr;105(4):341-8. doi: 10.1007/s00392-015-0926-0. Epub 2015 Oct 23.
10
Normalization of left ventricular ejection fraction after cardiac resynchronization therapy also normalizes survival.心脏再同步治疗后左心室射血分数的正常化也使生存率正常化。
Pacing Clin Electrophysiol. 2013 Aug;36(8):970-7. doi: 10.1111/pace.12174. Epub 2013 May 29.

引用本文的文献

1
Acute effect of multipoint pacing and fused AV delay in patients receiving cardiac resynchronization therapy.心脏再同步治疗患者中多点起搏和融合房室延迟的急性效应
J Arrhythm. 2025 May 12;41(3):e70085. doi: 10.1002/joa3.70085. eCollection 2025 Jun.
2
Abnormal conduction-induced cardiomyopathy: a poorly explored entity.异常传导所致心肌病:一个研究甚少的实体。
Eur Heart J Suppl. 2024 Apr 17;26(Suppl 1):i117-i122. doi: 10.1093/eurheartjsupp/suae028. eCollection 2024 Apr.
3
Impact of DCM-Causing Genetic Background on Long-Term Response to Cardiac Resynchronization Therapy.
致心律失常性右室心肌病相关基因突变背景对心脏再同步化治疗长期反应的影响。
JACC Clin Electrophysiol. 2024 Jul;10(7 Pt 1):1455-1464. doi: 10.1016/j.jacep.2024.03.019. Epub 2024 May 22.
4
The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy.扩张型心肌病初诊后使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂及β受体阻滞剂后的完全逆转效应。
J Res Med Sci. 2023 Aug 24;28:67. doi: 10.4103/jrms.jrms_626_21. eCollection 2023.
5
Follow-up of CRT-D patients downgraded to CRT-P at the time of generator exchange.在发生器更换时降级为心脏再同步治疗-起搏器(CRT-P)的心脏再同步治疗-除颤器(CRT-D)患者的随访
Front Cardiovasc Med. 2023 Jun 15;10:1217523. doi: 10.3389/fcvm.2023.1217523. eCollection 2023.
6
A machine learning method integrating ECG and gated SPECT for cardiac resynchronization therapy decision support.一种结合心电图和门控 SPECT 的机器学习方法,用于心脏再同步治疗决策支持。
Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3022-3033. doi: 10.1007/s00259-023-06259-4. Epub 2023 May 17.
7
Clinical impacts of scar reduction on gated myocardial perfusion SPECT after cardiac resynchronization therapy.心脏再同步化治疗后门控心肌灌注 SPECT 中瘢痕减少的临床影响。
J Nucl Cardiol. 2022 Oct;29(5):2571-2579. doi: 10.1007/s12350-021-02722-7. Epub 2021 Aug 19.
8
Downgrade of cardiac defibrillator devices to pacemakers in elderly heart failure patients: clinical considerations and the importance of shared decision-making.老年心力衰竭患者心脏除颤器装置降级为起搏器:临床考量与共同决策的重要性
Neth Heart J. 2021 May;29(5):243-252. doi: 10.1007/s12471-021-01555-w. Epub 2021 Mar 12.
9
Incremental value of left ventricular shape parameters measured by gated SPECT MPI in predicting the super-response to CRT.门控 SPECT MPI 测量的左心室形态参数对预测 CRT 超级反应的增量价值。
J Nucl Cardiol. 2022 Aug;29(4):1537-1546. doi: 10.1007/s12350-020-02469-7. Epub 2021 Jan 27.
10
Does 'super-responder' patients to cardiac resynchronization therapy still have indications for neuro-hormonal antagonists? Evidence from long-term follow-up in a single center.心脏再同步治疗的“超级反应者”患者是否仍有使用神经激素拮抗剂的指征?来自单中心长期随访的证据。
J Geriatr Cardiol. 2019 Mar;16(3):251-258. doi: 10.11909/j.issn.1671-5411.2019.03.015.